Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 106, Issue -, Pages 88-103Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2016.02.007
Keywords
Red blood cells; Erythrocytes; Drug delivery; Diagnostics; Nanoparticles
Categories
Funding
- National Institutes of Health [R01 HL121134, R01 HL125462]
Ask authors/readers for more resources
Red blood cells (RBCs) constitute a unique drug delivery system as a biologic or hybrid carrier capable of greatly enhancing pharmacokinetics, altering pharmacodynamics (for example, by changing margination within the intravascular space), and modulating immune responses to appended cargoes. Strategies for RBC drug delivery systems include internal and surface loading, and the latter can be performed both ex vivo and in vivo. A relatively new avenue for RBC drug delivery is their application as a carrier for nanoparticles. Efforts are also being made to incorporate features of RBCs in nanocarriers to mimic their most useful aspects, such as long circulation and stealth features. RBCs have also recently been explored as carriers for the delivery of antigens for modulation of immune response. Therefore, RBC-based drug delivery systems represent supercarriers for a diverse array of biomedical interventions, and this is reflected by several industrial and academic efforts that are poised to enter the clinical realm. (C) 2016 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available